Hemato Oncology Testing Market Size & Growth
As per the latest research findings
by GME, the Hemato
Oncology Testing Market will grow speedily at a 13.8% CAGR rate
from the 2020 to 2026 forecast period. The demand for hemato oncology testing is
projected due to the increasing number of patients clubbed with rising demand
for customized medicines
Browse 158 Market Data Tables and 119
Figures spread through 185 Pages and in-depth TOC on "Hemato Oncology
Testing Market - Forecast to 2026"
https://www.globalmarketestimates.com/market-report/global-hemato-oncology-testing-market-2404
By Cancer
Type (Leukemia, Lymphoma, Myeloproliferative Neoplasms, Other Cancers), By
Product Type (Assay Kits and Reagents, Services), By Technology (PCR, IHC, NGS,
Cytogenetics, Other Technologies), By End-Use (Hospitals, Academic &
Research Institutes, Others), By Region (North America,
Europe, Asia Pacific and Rest of the World); and Company Market Share Analysis
& Competitor Analysis
Key
Market Insights
·
The vital analysis of blood diseases such as iron deficiency
anemia, leukemia, lymphoma, sickle cell disease, and hemophilia includes hemato
oncology research.
·
The growing technological advancements in the oncology
testing market are yielding growthduring
the forecast period
·
The servicessegment is ought to grow faster than the product segment
considering year on year increasing demand for post-sale services.
·
Amongst all the instruments, the PCR segment is
ought to have the largest market share considering the huge number of samples
run on the instrument.
Major
players in the hemato oncology testing market include are EntroGen, Inc., F.
Hoffman-La Roche Ltd., Cepheid, Bio-Rad Laboratories, Inc., Invivoscribe, Inc.,
Adaptive Biotechnologies, Cepheid, Amoy Diagnostics Co., Ltd., Abbott
Laboratories, Qiagen N.V., Thermo Fisher Scientific, Inc., Illumina, Inc.,
Adaptive Biotechnologies, among others.
Browse
the Report @ https://www.globalmarketestimates.com/market-report/global-hemato-oncology-testing-market-2404
Cancer TypeOutlook (Revenue, USD Million, 2020-2026)
·
Leukemia
·
Acute Myeloid Leukemia (AML)
·
Acute Lymphocytic Leukemia (ALL)
·
Chronic Lymphocytic Leukemia
·
Chronic Myeloid Leukemia
·
Lymphoma
·
Hodgkin Lymphoma
·
Non-Hodgkin Lymphoma
·
Myeloproliferative Neoplasms
·
Polycythemia vera (PV)
·
Essential thrombocythemia (ET)
·
Myelofibrosis (MF)
·
Other Cancers
Product
Type (Revenue, USD Million, 2020-2026)
·
Assay Kits and
Reagents
·
Services
TechnologyOutlook (Revenue, USD Million, 2020-2026)
·
PCR
·
Real-time PCR
·
Digital PCR
·
IHC
·
NGS
·
Cytogenetics
·
Other Technologies
End-UseOutlook (Revenue, USD
Million, 2020-2026)
·
Hospitals
·
Academic & Research Institutes
·
Others
Regional Outlook (Revenue, USD
Million, 2020-2026)
North
America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest
of Europe
Asia Pacific
- China
- India
- Japan
- South
Korea
- Australia
- Rest
of APAC
Central & South America
- Brazil
- Argentina
- Chile
- Rest
of CSA
Middle East & Africa
- Saudi
Arabia
- South
Africa
- UAE
- Rest
of MEA
Contact:
Tracy Simon
Email
address: tracy.simon@globalmarketestimates.com
Phone
Number: +16026667238
Website:
https://www.globalmarketestimates.com/
Check
our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php
Comments
Post a Comment